Hepatology News

Treatment with lonafarnib boosted with ritonavir, with or without peginterferon alfa, resulted in significant virological and biochemical response in patients with chronic hepatitis D virus infection, according to data presented.

The U.S. Supreme Court ruled against the use of affirmative action programs during admissions processes at colleges and universities, potentially reducing the number of underrepresented students in medical education, experts said.

An analysis of data from 2013 to 2022 showed that only 34% of people diagnosed with hepatitis C in the United States were cured or cleared of the virus, with many still lacking access to highly effective treatments.

Endoscopic sleeve gastroplasty was more effective for weight loss than lifestyle modification alone in patients with nonalcoholic steatohepatitis and obesity, according to a speaker at EASL Congress.

In a Healio video exclusive, Laura Targownik, MD, FRCPC, urged gastroenterology societies to limit hosting conferences or events in states that have passed “bathroom laws” and other laws targeting transgender and gender nonconforming people.

The ACG has created a new clinical guideline based on existing data and expert opinion to aid clinicians in the diagnosis and management of patients with acute liver failure, with a focus on specific etiologies and disease presentation.

Chronic hepatitis B virus infection was significantly associated with an increased risk for intracerebral hemorrhage but not other types of stroke in Chinese adults, according to data presented at the EASL Congress.

Scoring systems based on behavioral and clinical data outperformed existing scores in predicting risk for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, according to data presented at the EASL Congress.

Fecal microbiota transplantation improved gut barrier function, mucosal immunity and ammonia metabolism in patients with cirrhosis, which could reduce hepatic encephalopathy and other infections, according to data from the PROFIT trial.

Naltrexone was effective in achieving abstinence, reducing lapses and improving craving scores at 3 months in patients with alcohol-related cirrhosis, according to data presented at EASL Congress.